Market Expansions, FDA Clearance, Updated Products, Dual Listings, and Legal Actions - Research Report on Zimmer, Varian, Allscripts, ResMed, and OPKO

NEW YORK, September 3, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Investors' Reports announced new research reports highlighting Zimmer Holdings, Inc. (NYSE: ZMH), Varian Medical Systems, Inc. (NYSE: VAR), Allscripts Healthcare Solutions, Inc. (NASDAQ: MDRX), ResMed Inc. (NYSE: RMD), and OPKO Health, Inc. (NYSE: OPK). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Zimmer Holdings, Inc. Research Report  

On August 23, 2013, Zimmer Holdings, Inc. (Zimmer) announced that it has received 510(k) clearance from the US FDA to market the Zimmer Patient Specific Instruments (PSI) Shoulder system to complement its Trabecular Metal Reverse shoulder system for reverse shoulder arthroplasty (RSA) procedures. According to the Company, its Zimmer PSI Shoulder uses 3D visualization software that allows a surgeon to create a customized surgical plan for each patient, and then provides patient-specific surgical instrument guides to facilitate placement of the implant corresponding to the personalized surgical plan. The Company further stated that its Zimmer PSI Shoulder is available to few surgeons in Europe since May 2013, and it intends to make the same available to shoulder surgeons across the US. "With PSI Shoulder, we present our surgeon customers with a powerful new tool to plan the glenoid side of the surgery with the patient's unique anatomy in full view and functional needs in mind, resulting in a physical reference in the operating room to complete the surgery with confidence," said Roberto Munoz, Vice President and General Manager of Zimmer Extremities. The Full Research Report on Zimmer Holdings, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-27/ZMH]

--

Varian Medical Systems, Inc. Research Report

On August 27, 2013, Varian Medical Systems, Inc. (Varian) announced that the clinical deployment of the country's first Varian TrueBeam medical linear accelerator have provided several Lebanese cancer patients access to fast and precise radiotherapy and radiosurgery treatments. According to the Company, its TrueBeam system, which is designed to treat a moving tumor with speed and accuracy, also incorporates numerous technical innovations that dynamically synchronize imaging, patient positioning, motion management, and treatment delivery during a radiotherapy or radiosurgery procedure. "TrueBeam is a versatile system able to handle different treatment techniques covering multiple clinical situations," said Dr. Elie Nasr, Professor and Chairman of Hotel-Dieu de France Hospital. Dr. Nasr added, "Until we installed TrueBeam we only offered our patients 3D conformal treatments but we are now able to routinely offer RapidArc image-guided VMAT treatments for all prostate cancer patients. This technique delivers high quality treatment plans while keeping treatment time to a minimum, which translates into short treatment times for patients." The Full Research Report on Varian Medical Systems, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-27/VAR]

--

Allscripts Healthcare Solutions, Inc. Research Report

On August 20, 2013, Allscripts Healthcare Solutions, Inc. (Allscripts) announced the availability of Allscripts Wand 2.0 for Enterprise EHR. According to the Company, its new version of Wand supports the physician's workflow with functionalities that clinicians and physicians alike need to complete a patient visit with one mobile device. "We listened to our clients and broke new ground with the 2.0 version of Wand for Enterprise," said Stanley Crane, Chief Innovation Officer of Allscripts. "What we have delivered is a mobile tool with a streamlined workflow and faster access to critical data - where and when the physicians need it most - in their hands at the point of care." The Full Research Report on Allscripts Healthcare Solutions, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-27/MDRX]

--

ResMed Inc. Research Report

On August 21, 2013, ResMed Inc. (ResMed) announced that the International Trade Commission has agreed to investigate BMC Medical Co., Ltd. (BMC), and its distributors 3B Medical Inc. (3B Medical) and 3B Products, L.L.C. (3B Products). According to the Company, the investigation was initiated at the request of ResMed, upon filing suit in federal court against BMC in May 2013, asserting infringement of patents by the RESmart CPAP and RESmart Auto CPAP devices and the Willow nasal pillows patient interface, as well as the iVolve nasal mask. The Full Research Report on ResMed Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-27/RMD]

--

OPKO Health, Inc. Research Report

On August 19, 2013, OPKO Health, Inc. (OPKO) announced that the Tel-Aviv Stock Exchange (TASE) has approved the new listing of the Company's common stock on the TASE, effective from August 21, 2013, under the ticker symbol OPK. According to the Company, pursuant to the approval, its common stock will thereafter be listed on both the NYSE in the US and the TASE in Israel.  "We are pleased to start trading on the TASE with this dual listing and to join Israel's top companies as part of the TA-25 index. We believe that this step will expand our exposure to the Israeli investment community and will increase the interest in OPKO among Israel's large and sophisticated institutional investors," said Dr. Phillip Frost, Chairman and CEO of OPKO. The Full Research Report on OPKO Health, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-28/OPK]

----

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

http://www.investorsreports.com

SOURCE Investors' Reports